KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Moderna (MRNA) EBIT: 2016-2024

Historic EBIT for Moderna (MRNA) over the last 9 years, with Dec 2024 value amounting to -$3.9 billion.

  • Moderna's EBIT fell 271.43% to -$260.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.5 billion, marking a year-over-year decrease of 28.59%. This contributed to the annual value of -$3.9 billion for FY2024, which is 6.94% up from last year.
  • Moderna's EBIT amounted to -$3.9 billion in FY2024, which was up 6.94% from -$4.2 billion recorded in FY2023.
  • Over the past 5 years, Moderna's EBIT peaked at $13.3 billion during FY2021, and registered a low of -$4.2 billion during FY2023.
  • For the 3-year period, Moderna's EBIT averaged around $412.0 million, with its median value being -$3.9 billion (2024).
  • In the last 5 years, Moderna's EBIT skyrocketed by 1,842.60% in 2021 and then tumbled by 145.00% in 2023.
  • Moderna's EBIT (Yearly) stood at -$763.0 million in 2020, then spiked by 1,842.60% to $13.3 billion in 2021, then fell by 29.15% to $9.4 billion in 2022, then slumped by 145.00% to -$4.2 billion in 2023, then rose by 6.94% to -$3.9 billion in 2024.